Clinical efficacy of antiviral therapy in patients with hepatitis B-related cirrhosis after transjugular intrahepatic portosystemic shunt

Figure 1 Overall survival, hepatic encephalopathy free survival, and hepatocellular carcinoma free survival rate in tenofovir alafenamide fumarate, tenofovir disoproxil fumarate, and entecavir groups. A: Survival; B: Freedom from hepatic encephalopathy; C: Freedom from hepatocellular carcinoma. HCC: Hepatocellular carcinoma; HE: Hepatic encephalopathy; TAF: Tenofovir alafenamide fumarate; TDF: Tenofovir disoproxil fumarate; ETV: Entecavir.

Figure 2 Preoperative and postoperative Child-Pugh scores and ratios in the three patient groups. TAF: Tenofovir alafenamide fumarate; TDF: Tenofovir disoproxil fumarate; ETV: Entecavir.

Figure 3 Changes in preoperative and postoperative model for end-stage liver disease scores in the three patient groups. MELD: Model for end-stage liver disease; TAF: Tenofovir alafenamide fumarate; TDF: Tenofovir disoproxil fumarate; ETV: Entecavir.

Figure 4 Changes in preoperative and postoperative estimated glomerular filtration rates in the three patient groups. eGFR: Estimated glomerular filtration rate; TAF: Tenofovir alafenamide fumarate; TDF: Tenofovir disoproxil fumarate; ETV: Entecavir.